Quoin Pharmaceuticals Ltd. (QNRX) reports news about a late clinical-stage specialty pharmaceutical company developing therapies for rare and orphan diseases. Updates center on QRX003 lotion for Netherton Syndrome and related rare skin disorders, including clinical-study progress and U.S. and European orphan, rare pediatric disease and fast track regulatory designations.
Company news also covers QRX009 topical rapamycin development programs, rare dermatologic and genetic disease research, quarterly financial results, private-placement financing and distribution or commercialization arrangements for potential international markets.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) received a notification from Nasdaq on June 10, 2022, indicating non-compliance with the minimum bid price requirement of $1.00 per share, necessitating corrective action within 180 days. This notification does not currently affect its Nasdaq listing. The company is also addressing earlier non-compliance regarding stockholders’ equity, having submitted a plan to Nasdaq for resolution. While the company remains operationally unaffected, the prospect of delisting poses a significant risk to shareholders.
Quoin Pharmaceuticals has announced a significant agreement with Hong Kong WinHealth Pharma Group to license and distribute its lead product QRX003 for Netherton Syndrome in Greater China.
The agreement will expand access to rare disease treatments in Hong Kong, Macau, and Taiwan, contingent on regulatory approval, and brings Quoin's global partnerships for QRX003 to nearly 60 countries. With QRX003 potentially being the first treatment for this rare condition, clinical trials are expected to commence shortly.
Skinvisible, Inc. (OTCQB:SKVI) has announced that its licensee Quoin Pharmaceuticals (NASDAQ:QNRX) received FDA acceptance for an Investigational New Drug (IND) application for QRX003, a treatment for Netherton Syndrome. This marks the first IND approval using Skinvisible's proprietary Invisicare drug delivery technology. Successful clinical trials could lead to a milestone payment of $5 million and ongoing royalties for Skinvisible. The approval underscores the potential for expanding applications of their technology in treating rare skin disorders.
Quoin Pharmaceuticals has secured exclusive global rights to a product in development for scleroderma through a new agreement with Queensland University of Technology. This deal involves no upfront fees and allows Quoin to fund the pre-clinical program. The VCAM-1:VL-4 interaction targets immune response in scleroderma, a disease with no current cure. Additionally, Quoin received FDA clearance for its lead product, QRX003, targeting Netherton Syndrome, with clinical trials set to begin in Q2 2022. This positions Quoin to potentially deliver groundbreaking treatments for rare diseases.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has received FDA clearance to initiate clinical testing for its investigational product QRX003, aimed at treating Netherton Syndrome, a rare genetic condition with no current approved treatments. QRX003, a topical lotion that uses proprietary delivery technology, seeks to normalize skin shedding and improve skin barrier function. The company plans to begin clinical trials in the first half of 2022, marking a significant milestone for both Quoin and patients suffering from this serious condition.
Quoin Pharmaceuticals has submitted an Investigational New Drug (IND) application to the FDA for its investigational product QRX003, targeting Netherton Syndrome, a rare genetic disorder with no current treatment options. QRX003 is a topical lotion formulated to restore the skin barrier in affected patients. This IND submission represents a significant milestone for the company as it aims to initiate clinical testing in Q2 2022. Quoin's pipeline also includes additional products for rare diseases, highlighting its commitment to addressing unmet medical needs.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has submitted a Scientific Advice Briefing Document to the European Medicines Agency (EMA) for QRX003, aimed at treating Netherton Syndrome, a rare genetic disease with no current cure. This submission is a critical first step towards advancing the treatment into clinical testing and potential commercialization in the EU. The company has integrated previous feedback received from the FDA into this submission, reflecting its commitment to addressing unmet medical needs in rare diseases.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has expanded its partnership with ER-Kim to include six additional countries for the commercialization of QRX003, a treatment for Netherton Syndrome. This new agreement adds Turkey, Georgia, Azerbaijan, Greece, Cyprus, and Malta to the existing fifteen countries covered in the initial agreement. With this expansion, Quoin now has a total of 60 countries under distribution agreements for QRX003, which aims to be the first approved treatment for this rare genetic disorder lacking current therapies.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive agreement with Neopharm Medical Supplies to commercialize its investigational drug QRX003 in Israel. This marks the sixth distribution partnership for QRX003 since Quoin's NASDAQ debut in October 2021. The agreement aims to address Netherton Syndrome, a rare genetic disorder with no existing treatment. Quoin's CEO, Dr. Michael Myers, emphasized the importance of expanding the distribution network to ensure global access for patients once the product is approved.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has secured an exclusive distribution agreement with ER-Kim to commercialize its investigational treatment QRX003 across 15 Central and Eastern European countries. This marks Quoin's fifth distribution partnership since its public debut in October 2021, expanding its access to Netherton Syndrome patients in crucial regions. With this agreement, Quoin now has partnerships in a total of 53 countries, reaffirming its commitment to providing treatment options for this rare genetic disease.